|
gptkbp:instanceOf
|
Medical Treatment
|
|
gptkbp:approvedBy
|
gptkb:China
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:canBe
|
Allogeneic Cells
Autologous Cells
Engineered Cells
Xenogeneic Cells
|
|
gptkbp:challenge
|
Regulatory Approval
Cost
Long-term Safety
Manufacturing Scale-up
|
|
gptkbp:deliveredBy
|
Intravenous Injection
Local Injection
Surgical Implantation
|
|
gptkbp:goal
|
Deliver Therapeutic Agents
Modulate Immune Response
Replace Damaged Cells
Restore Function
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cell Therapy
|
|
gptkbp:includes
|
gptkb:CAR-T_Cell_Therapy
gptkb:Dendritic_Cell_Therapy
gptkb:NK_Cell_Therapy
gptkb:Stem_Cell_Therapy
gptkb:T_Cell_Therapy
|
|
gptkbp:introducedIn
|
20th Century
|
|
gptkbp:method
|
Transplantation of Living Cells
|
|
gptkbp:notableExample
|
gptkb:CAR-T_Cell_Therapy_for_Leukemia
gptkb:Hematopoietic_Stem_Cell_Transplantation
gptkb:Mesenchymal_Stem_Cell_Therapy
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:relatedTo
|
gptkb:Gene_Therapy
immunotherapy
Tissue Engineering
|
|
gptkbp:requires
|
Quality Control
Cryopreservation
Cell Characterization
Cell Expansion
Cell Isolation
|
|
gptkbp:riskFactor
|
gptkb:Graft-versus-host_Disease
Infection
Immune Rejection
Tumor Formation
|
|
gptkbp:studiedBy
|
Pharmaceutical Companies
Academic Institutions
Biotechnology Companies
|
|
gptkbp:usedFor
|
gptkb:Regenerative_Medicine
Autoimmune Disease Treatment
Cancer Treatment
Genetic Disorder Treatment
|
|
gptkbp:bfsParent
|
gptkb:Goodie_Mob
|
|
gptkbp:bfsLayer
|
5
|